Mayne Pharma Group Ltd
Company Profile
Business description
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women’s Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women’s Health segment distributes branded women’s health products in the U.S. International’s segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
Contact
1538 Main North Road
Salisbury South
SalisburySA5106
AUST: +61 882092666
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
30 June 2026
Employees
160
Mayne Pharma Group Ltd News & Analysis
stocks
Mayne Pharma woes to persist for 2020
stocks
How the Morningstar Best Ideas list did in 2019
stocks
Scott and Josh take note: our strategic assets are off limits
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,178.00 | 28.70 | -0.31% |
| CAC 40 | 8,134.09 | 66.79 | -0.81% |
| DAX 40 | 24,032.11 | 86.78 | -0.36% |
| Dow JONES (US) | 47,522.12 | 109.88 | -0.23% |
| FTSE 100 | 9,725.08 | 34.98 | -0.36% |
| HKSE | 25,906.65 | 376.04 | -1.43% |
| NASDAQ | 23,581.14 | 377.33 | -1.57% |
| Nikkei 225 | 52,411.34 | 1,085.73 | 2.12% |
| NZX 50 Index | 13,548.32 | 89.03 | 0.66% |
| S&P 500 | 6,822.34 | 68.25 | -0.99% |
| S&P/ASX 200 | 8,881.90 | 31.30 | -0.35% |
| SSE Composite Index | 3,954.79 | 32.11 | -0.81% |